Cardiome Pharma Corporation (CRME)
Cardiome Pharma Corporation SG&A Expense: 2.10M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
CRME SG&A Expense Rankings
| Overall | 90th percentile | 386 of 4190 |
| Sector | 82nd percentile | 84 of 485 in Healthcare |
| Industry | 82nd percentile | 7 of 39 in Drug Manufacturers - Other |
CRME SG&A Expense Range, Past 5 Years
| Minimum | 2.10M | Dec 2011 |
| Maximum | 5.01M | Dec 2007 |
| Average | 3.631M |
About SG&A Expense
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
The details of how SG&A expenses are calculated vary widely from company to company, so YCharts recommends looking at the annual report (10-k) an investor is interested in dissecting this number further.
Learn More
You may also be interested in these CRME related companies
CRME News
This company is amazing! A brick is more creative, eloquent and energetic than this $CRME management.
about 10 days ago by OysterX
about 10 days ago by OysterX
Very Interesting One : $CRME ( 0.70 ) This One Will Head Back Over a Buck ! Add On Your Watchlist And Keep An Eye On It ...
about 58 days ago by WallStreetBeats
about 58 days ago by WallStreetBeats
@PIER $CRME I have a feeling it may take a while. could test new lows, though the market hasn't helped.. but its a good buy here
about 60 days ago by peoples
about 60 days ago by peoples
$CRME With Merck calling it quits, is there a possibility that another big player might swoop in? Just wondering.
about 66 days ago by MarketBuy
about 66 days ago by MarketBuy
$CRME Long at .785. Let's go. Merck pullout just a minor setback. PPS is lower than book or cash per share! Easy long!
about 66 days ago by MarketBuy
about 66 days ago by MarketBuy
$CRME they have the cash on hand and it is equal or even more than share price.. its an easy buy
about 68 days ago by peoples
about 68 days ago by peoples
$CRME master at catching a falling knife... and it is not yet... but coming
about 70 days ago by peoples
about 70 days ago by peoples
$CRME I'll let you guys know when to buy.. it is starting to look interesting... sorry for those who thought they are getting in right
about 70 days ago by peoples
about 70 days ago by peoples
Oppenheimer Downgrades Cardiome Pharmaoration from Outperform to Perform, Removes PT from $ to $
Mar 19, 2:25PM Benzinga
Mar 19, 2:25PM Benzinga
$CRME Funny, this morning's plungle probably caused a few heart attacks. Ironic? A little.
about 70 days ago by MarketBuy
about 70 days ago by MarketBuy
Cardiome Announces Positive Phase 1 PK/PD Trial Results for Vernakalant Oral
Nov 03, 5:09PM GlobeNewswire
Nov 03, 5:09PM GlobeNewswire
Cardiome should benefit from significant vernakalant progress, says Oppenheimer
Sep 12, 7:28AM FlyOnTheWall
Sep 12, 7:28AM FlyOnTheWall
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CRME | 0.44 | +0.01 | +2.33% | 26.90M |
| CRMD | 0.27 | -0.01 | -3.50% | 3.081M |
| CRM | 147.00 | +0.79 | +0.54% | 20.14B |
| CRL | 33.56 | +0.21 | +0.63% | 1.641B |
| CPA | 83.85 | +0.62 | +0.74% | 3.713B |
| CP | 74.95 | -0.57 | -0.75% | 12.81B |
| COY | 7.40 | -0.04 | -0.54% | |
| COWN | 2.39 | +0.00 | +0.00% | |
| COVR | 1.54 | +0.00 | +0.00% | 39.42M |
| COV | 53.32 | -0.14 | -0.26% | 25.77B |
